C4 Therapeutics is harnessing the innate power of the body to control the quality of proteins within cells. Our approach uses drugs to target disease-causing proteins for destruction. This breakthrough technology offers many advantages for the treatment of cancer and other diseases, while avoiding traditional drug resistance.
C4 Therapeutics Announces Appointment of Andrew Phillips, Ph.D. as President and CEO
WATERTOWN, MA May 3, 2018 - C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been appointed as President and Chief Executive Officer. Dr. Phillips has been leading C4T’s scientific efforts as Chief Scientific Officer since January 2016 and assumed corporate leadership responsibilities with his added appointment as President in September 2016. In conjunction with Dr. Phillips appointment as CEO, Stewart Fisher, Ph.D., has been promoted to Chief Scientific Officer.
“Andy has played a key role in C4T’s growth and has helped define who we are today as a Company,” said Marc Cohen, co-founder and Executive Chairman of C4T. “In addition to being a world-class scientist, Andy has provided exemplary leadership in recruiting a phenomenal read more...
C4 Therapeutics Announces Promotion of Stewart Fisher, Ph.D. to Chief Scientific Officer
WATERTOWN, MA May 3, 2018 - C4 Therapeutics (C4T) today announced that Stewart Fisher, Ph.D. has been promoted to Chief Scientific Officer. Since joining C4T as Senior Vice President of Discovery Sciences in April 2016, Dr. Fisher has played a leading role in cultivating C4T’s targeted protein degradation platform and contributing to the growth of the Company’s internal pipeline.
“Stew has been central to the development of our platform for targeted protein degradation,” said Andy Phillips, President and Chief Executive Officer of C4T. “His deep expertise in quantitative aspects of drug discovery has transformed our approach to the discovery of degraders and has provided many mechanistic insights read more...
Publication on Degradation Technologies Licensed from Dana-Farber Cancer Institute
CAMBRIDGE, MA March 26, 2018 - C4 Therapeutics (C4T) today announced that an independent study featuring targeted protein degradation technologies licensed by the Company from Dana-Farber Cancer Institute were published in Nature Chemical Biology. The paper (DOI: 10.1038/s41589-018-0021-8) describes a system using a degradation tag (dTAG) for proteins that is broadly applicable to target validation for drug discovery.
“Degradation has emerged as an exciting new direction for drug discovery and the dTAG system allows the rapid degradation of engineered proteins for target validation and biological investigation,” said Dr. Nathanael read more...
What We Do
R&D / Strategic Alliances Project Management
Director, Drug Discovery Chemistry
Senior Research Scientist, Medicinal Chemistry
Research Scientist, Chemistry
QSP Modeler/ DMPK Project Team Representative
Senior Research Scientist/Associate Director, Translational Biology
Senior Manager/Associate Director of FP&A
DMPK Project Team Representative